Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 7/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491903 | 0.84 | GRIK1 (0.42) | SMYD3SMN1; SMN2HPGDCYP3A4CYP2C19 | |
| SCHEMBL10132091 | 0.81 | LMNA (0.56) | LMNABLMKMT2ASMYD3SMN1; SMN2 | |
| SCHEMBL7373390 | 0.78 | SLC7A5 (0.47) | LMNABLMKMT2ASMYD3SMN1; SMN2 | |
| SCHEMBL7373388 | 0.78 | SLC7A5 (0.47) | LMNABLMKMT2ASMYD3SMN1; SMN2 | |
| SCHEMBL6876246 | 0.78 | SMYD3 (0.56) | SMYD3HPGDCYP3A4CYP2C19RAB9A | |
| SCHEMBL15085653 | 0.78 | SMYD3 (0.56) | SMYD3HPGDCYP3A4CYP2C19RAB9A | |
| SCHEMBL15844692 | 0.78 | LMNA (0.45) | LMNABLMKMT2ASMYD3SMN1; SMN2 | |
| SCHEMBL2345431 | 0.78 | LMNA (0.49) | LMNABLMKMT2ASMYD3EPHX1 | |
| Hydrochloric Acid SCHEMBL29244862 | 0.78 | LMNA (0.45) | LMNABLMKMT2ASMYD3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5114605 | 0.78 | LMNA (0.45) | LMNABLMKMT2ASMYD3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101186-B2 | Peptides that block the binding of IgG to FcRn | SYNTONIX PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | BIOGEN HEMOPHILIA INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | FCGRT, FCGR3B, FCGR1A | LMNA 4348/4885BLM 4411/4885KMT2A 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.